ArticleScience advances2025
Radiotranscriptomics in papillary thyroid carcinoma complement current noninvasive risk stratification system.
Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ultrasound radiomics for preoperative evaluation of Ki-67 proliferation index in papillary thyroid carcinoma.Frontiers in oncology · 2026Article
- Averting crisis in severe tracheal stenosis and fistula following thyroidectomy: a case report.BMC surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Papillary thyroid carcinoma (PTC) generally has a favorable prognosis; however, overtreatment persists because of the lack of reliable noninvasive risk stratification tools. This study developed a radiomics-based approach to enhance the preoperative assessment of PTC. Imaging features from 255 patients were analyzed, and three tumor clusters were identified via unsupervised clustering, with one cluster (Cluster 2) displaying favorable clinical and molecular profiles. A radiomics score was constructed and validated internally and externally, achieving high diagnostic accuracy (area under the curve of 0.98) and independently predicting benign features such as a lower N stage and favorable treatment responses. Transcriptomic analysis revealed immune activation and survival-related gene expression in Cluster 2. The model demonstrated robust performance in stratifying patients for active surveillance and may complement current diagnostic frameworks, offering a precise, noninvasive tool to guide clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.